Claire Lockey - Tricida President

TCDADelisted Stock  USD 0.01  0.0001  0.71%   

President

Ms. Claire J. Lockey serves as Senior Vice President and Chief Development Officer of the Company. Ms. Lockey has served as our Senior Vice President and Chief Development Officer since November 2015. Ms. Lockey served as the Senior Vice President of Pharmaceutical Development and Regulatory Affairs at Relypsa, Inc. from February 2010 until November 2015 since 2015.
Age 65
Tenure 9 years
Phone415 429 7800
Webhttps://www.tricida.com
Lockey served as Vice President of Regulatory Affairs at FibroGen, Inc. from July 2003 until January 2010 and has held similar executivelevel positions at other biopharmaceutical companies including Titan Pharmaceuticals, Inc., Layton Bioscience, Inc., Connetics Corporationration and Gore Hybrid Technologies, Inc., as well as a consulting position at Synergia LLC from 1985 until 1995. She received a B.A. in Biology from Boston University.

Tricida Management Efficiency

The company has return on total asset (ROA) of (0.6011) % which means that it has lost $0.6011 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.2371) %, meaning that it created substantial loss on money invested by shareholders. Tricida's management efficiency ratios could be used to measure how well Tricida manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 127.51 M in liabilities. Tricida has a current ratio of 5.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Tricida until it has trouble settling it off, either with new capital or with free cash flow. So, Tricida's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Tricida sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Tricida to invest in growth at high rates of return. When we think about Tricida's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

John LinkerJeld Wen Holding
45
Steven RaiaTopbuild Corp
69
Robert KuhnsTopbuild Corp
49
Julia LeemanCECO Environmental Corp
N/A
Aref MatinJohn Wiley Sons
65
Peter FarmakisJeld Wen Holding
52
David CzeszewskiCECO Environmental Corp
54
David GuernseyJeld Wen Holding
57
Diane JonesCECO Environmental Corp
48
Michelle FrielTopbuild Corp
45
Peter MaxwellJeld Wen Holding
55
Luis MachadoTopbuild Corp
61
Jeffrey KrestancicTopbuild Corp
40
John KlineCECO Environmental Corp
55
John DingerJeld Wen Holding
50
Mark PompaEMCOR Group
59
Christina TassellJohn Wiley Sons
52
Scott ViningJeld Wen Holding
61
Doug CraneyCECO Environmental Corp
N/A
Timothy CravenJeld Wen Holding
56
Andrew HurstCECO Environmental Corp
55
It focuses on the development and commercialization of veverimer , a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California. Tricida operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 57 people. Tricida (TCDA) is traded on NASDAQ Exchange in USA and employs 57 people.

Management Performance

Tricida Leadership Team

Elected by the shareholders, the Tricida's board of directors comprises two types of representatives: Tricida inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tricida. The board's role is to monitor Tricida's management team and ensure that shareholders' interests are well served. Tricida's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tricida's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jerry Buysse, Senior Vice President Chief Scientific Officer
Wilhelm Stahl, Senior Vice President CTO
Robert Alpern, Independent Director
Edward Hejlek, Senior Vice President General Counsel
Geoffrey Parker, CFO, Senior Vice President
David Hirsch, Independent Director
JD Esq, Ex Property
Claire Lockey, Senior Vice President and Chief Development Officer
David Bonita, Chairman of the Board
Sandra Coufal, Independent Director
Gerrit Klaerner, President CEO, Member of the Board of Directors
Annie Yoshiyama, VP Officer
Jeroen Beek, Chief Commercial Officer and Senior Vice President
Kathryn Falberg, Independent Director
Klaus Veitinger, Independent Chairman of the Board
Dawn Parsell, Senior Vice President - Clinical Development
Susannah Cantrell, Senior Vice President Chief Commercial Officer
Robert JD, Company VP
Jackie Cossmon, VP Communications

Tricida Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tricida a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Tricida in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Tricida's short interest history, or implied volatility extrapolated from Tricida options trading.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Note that the Tricida information on this page should be used as a complementary analysis to other Tricida's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Other Consideration for investing in Tricida Stock

If you are still planning to invest in Tricida check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tricida's history and understand the potential risks before investing.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
CEOs Directory
Screen CEOs from public companies around the world